Drug Trial Radar · NCT04565236
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
Last checked: Nov 20, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Sep 22, 2020
Primary completion
Mar 15, 2024
Study completion Mar 15, 2024
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 0 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia A. In addition, pharmacokinetic parameters of Kovaltry will be assessed in a subset of patients.
Conditions
- Hemophilia A
Interventions
Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1Biological
25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months. The dose decisions are at the discretion of the investigator.
Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2Biological
12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months. \>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months. The dose decisions are at the discretion of the investigator.
Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3Biological
15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week. The dose decisions are at the discretion of the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Bleeding Rate (ABR) of All Bleeding Episodes During Prophylaxis Treatment in Part ATime frame: Up to 6 months
- Annualized Bleeding Rate (ABR) of All Bleeding Episodes Within 48 Hours of Previous Prophylaxis Infusion in Part BTime frame: Up to 48 hours post-infusion during 6 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital CAMS
Beijing, China
Childrens Hospital of Shanghai
Shanghai, China
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The Children's Hospital Zhejiang University School of Med
Hangzhou, Hangzhou Province, China
Shijiazhuang General Hospital
Shijiazhuang, Hebei, China
NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
Nanjing, Jiangsu, China
1st Affiliated hospital of Soochow University
Suzhou, Jiangsu, China
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
Children's Hospital of Shanxi
Taiyuan, Shanxi, China
Chengdu Women & Children's Central Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.